TY - JOUR
T1 - Keynote Address at the ASBrS 2022 Annual Meeting Low-Risk Breast Cancer
T2 - When Is Local Therapy Enough?
AU - Klimberg, V. Suzanne
N1 - Publisher Copyright:
© 2022, Society of Surgical Oncology.
PY - 2022/10
Y1 - 2022/10
N2 - Surgery, radiation, and chemotherapy have all been used to de-escalate the treatment of breast cancer patients. Despite its impact on local recurrence, systemic endocrine therapy (ET) has yet to be de-escalated, even though it has substantial adverse effects and a lower quality of life (QoL) over 5–10 years. The 21-gene recurrence score (RS) and MammaPrint have been used to identify subgroups of younger patients whose long-term survival is unaffected by adjuvant ET. Local treatment only, with de-escalation of long-term systemic ET for patients aged 50–69 with RS < 11, appears not to impact OS and should have an anticipated improvement in QoL.
AB - Surgery, radiation, and chemotherapy have all been used to de-escalate the treatment of breast cancer patients. Despite its impact on local recurrence, systemic endocrine therapy (ET) has yet to be de-escalated, even though it has substantial adverse effects and a lower quality of life (QoL) over 5–10 years. The 21-gene recurrence score (RS) and MammaPrint have been used to identify subgroups of younger patients whose long-term survival is unaffected by adjuvant ET. Local treatment only, with de-escalation of long-term systemic ET for patients aged 50–69 with RS < 11, appears not to impact OS and should have an anticipated improvement in QoL.
UR - http://www.scopus.com/inward/record.url?scp=85135227551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135227551&partnerID=8YFLogxK
U2 - 10.1245/s10434-022-12125-8
DO - 10.1245/s10434-022-12125-8
M3 - Article
C2 - 35907998
AN - SCOPUS:85135227551
SN - 1068-9265
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
ER -